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Genome-wideassociationstudieshave identified73breastcancer riskvariantsmainly inEuropeanpopulations.
Given considerable differences in linkage disequilibrium structure between populations of European and
African ancestry, the known risk variants may not be informative for risk in African ancestry populations. In a
previous fine-mapping investigation of 19 breast cancer loci, we were able to identify SNPs in four regions
that better captured risk associations in African American women. In this study of breast cancer in African
American women (3016 cases, 2745 controls), we tested an additional 54 novel breast cancer risk variants.
Thirty-eight variants (70%) were found to have an association with breast cancer in the same direction as previ-
ously reported, with eight (15%) replicating at P < 0.05. Through fine-mapping, in three regions (1q32, 3p24,
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10q25), we identified variants that better captured associations with overall breast cancer or estrogen receptor
positive disease. We also observed suggestive associations with variants (at P < 5 3 1026) in three separate
regions (6q25, 14q13, 22q12) that may represent novel risk variants. Directional consistency of association
observed for ∼65–70% of currently known genetic variants for breast cancer in women of African ancestry im-
pliesasharedfunctionalcommonvariantatmost loci.Tovalidateandenhancethespectrumofalleles thatdefine
associations at the known breast cancer risk loci, as well as genome-wide, will require even larger collaborative
efforts in women of African ancestry.
INTRODUCTION
Genome-wide association studies (GWAS) have identified .70
risk variants for breast cancer (1–15). A large fraction of these
discoveries have recently come from the COGS consortium
which included follow-up testing of GWAS findings in 46
000 cases and 42 000 controls and revealed 41 loci for
overall breast cancer (12) and four loci associated with estrogen
receptor negative (ER2) but not ER positive (ER+) disease
(14). Most of the .70 variants that are associated with breast
cancer risk were found initially in women of European ancestry.
Exceptions include a small number of variants located at 6q25
found in Asians (6,15) and 5p15, which was identified in a multi-
ethnic GWAS meta-analysis that included women of African an-
cestry in the discovery stage (10). A clear limitation of GWAS in
non-European populations is sample size, and continued pooling
of GWAS data and large-scale replication testing will be needed
to reveal variants that may be unique to or are of particular im-
portance in specific populations. At the same time, comprehen-
sive testing of common genetic variation at known risk loci in
multiple racial and ethnic populations will be required to under-
stand the contribution of the locus to risk globally.
Population history has influenced recombination patterns,
linkage disequilibrium (LD) structure and the number and fre-
quency of polymorphic alleles between diverse populations.
Thus, in the context of exploring genetic variation at known
risk loci, a risk variant (i.e. ‘index signal’) found in European
populations might not serve as a surrogate of (or ‘tag’) the bio-
logically relevant risk variant in African ancestry populations.
In addition, the complete spectrum of possible biologically
meaningful genetic variation may not be examined if fine-
mapping is limited to the population in which the signal was
originally detected. We previously developed an analytic frame-
work for fine-mapping of common variation at GWAS risk loci
which we applied to testing of an initial set of 19 breast cancer
susceptibility regions in an attempt to search for genetic
markers that are the most informative for breast cancer risk in
women of African ancestry (Materials and Methods) (16). We
identified markers in four regions (2q35, 5q11, 10q26 and
19p13) that better capture the association with breast cancer
risk in African Americans in comparison to the original index
signal and thus are likely to be better markers of the biologically
functional alleles in this population. We also identified associa-
tions with markers in four separate regions (8q24, 10q22, 11q13
and 16q12) that are independent of the index signals and may re-
present putative novel risk variants.
In the present study, we have applied this analytical strategy to
examine an additional 54 risk variants for breast cancer in 3016
cases and 2745 controls that are part of a breast cancer GWAS in
African American women (16). In addition to testing the index
signals, we conducted fine-mapping across each locus in
search of risk variants that better define breast cancer risk in
African Americans as well as secondary signals that are un-
correlated with the index signal and may define novel risk
alleles. We also combine these new results with those from our
previous report of the 19 loci, and summarize the evidence
across all 73 loci.
RESULTS
For the 54 variants included in the analysis (38 genotyped and 16
imputed), the risk allele frequencies ranged from 0.003 for
rs11571833 (13q13) to 0.98 for rs1353747 (5q11); 47 variants
were appreciably common in African Americans with risk
allele frequencies .0.1 (Supplementary Material, Table S1).
Thirty-six of the 54 index variants (67%) showed positive asso-
ciations (OR . 1) with overall breast cancer risk that were direc-
tionally consistent with the initial report of these variants, with
seven nominally statistically significant at P , 0.05. Of the 54
variants (48 previously reported to be associated with overall
breast cancer and six reported to be specifically associated
with ER2 disease), statistical power to detect a nominally stat-
istically significant association was .80% for only two variants
(Supplementary Material, Table S2).
Figure 1 shows the associations of all 73 variants with breast
cancer risk in African Americans, which includes these 54 new
variants as well as the 19 variants reported in our previous
study (1–15). Of the 73 variants, 47 (64%) were positively asso-
ciated with breast cancer risk in African American women. For
11 variants, the 95% confidence intervals (CI) reported from
the previous studies excluded the ORs estimated in African
Americans and for only eight variants were the 95% CI non-
overlapping.
In analyses by ER status, 34 of the 54 (63%) variants were posi-
tively associated with ER+ breast cancer, with six significant at
P , 0.05. Thirty-one variants (57%) were positively associated
with ER2 breast cancer (Seven at P , 0.05) (Supplementary
Material,TableS3). Inthecase-onlyanalysis,fivevariantsshowed
a statistically significantly different association with breast cancer
risk by ER status: rs10759243/9q31 and rs13329835/16q23,
which were more strongly associated with ER+ disease and
rs10069690/5p15, rs1432679/5q33 and rs2284378/20q11 which
were more strongly associated with ER2 disease. These associa-
tions in ER subgroups were consistent with previous reports
of these loci (Supplementary Material, Table S3) (10,12,13,17).
Of the seven variants reported to be specifically associated
with ER2 breast cancer (rs6678914/1q32, rs4245739/1q32,
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Figure 1. Effect estimates of overall breast cancer risk for all 73 known risk variants in GWAS-discovery and African-ancestry populations. Red circles represent the
per-allele ORs estimated in women of African ancestry (AA). Blue diamonds represent the per-allele ORs reported in the initial GWAS. The horizontal lines represent
95% confidence limits. Asterisks represent SNPs that were reported for ER2 disease. For each tested allele, frequencies in GWAS-discovery and African-ancestry
populations are provided in parentheses. SNPs are sorted based on their ORs in AA. Detailed information for each SNP is provided in Supplementary Material,
Table S1.
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rs12710696/2p24, rs10069690/5p15, rs11075995/16q12,
rs8170/19p13, rs2284378/20q11) (7,10,13,14), we have previ-
ously reported positive associations for all seven variants, two
of which were significant at P , 0.05 (rs10069690 on 5p15
and rs2284378 on 20q11) (10,13,14,16). However, statistical
power was .80% to detect the associations for only ER2 var-
iants rs10069690 on 5p15, which this study contributed to iden-
tifying, and rs8170 on 19p13 (988 ER2 cases and all controls;
Supplementary Material, Table S2).
In addition to statistical power, the failure to replicate associa-
tions with the index variants implies that the particular risk
variant found in GWAS in European or Asian populations
might not be adequately correlated with the biologically relevant
allele in African Americans. In an attempt to identify a better
genetic marker of the biologically relevant allele in African
Americans, we tested all genotyped and imputed SNPs (in the
1000 Genomes Project) that were correlated (r2 . 0.4) with
the index variant in European ancestry populations (see Materi-
als and Methods for details of fine-mapping).
In three of the 54 regions (1q32, 3p24, 10q25), we found asso-
ciations with variants that might better define risk in African
Americans. The index variant on 1q32 (rs4245739) has been
reported for ER2 (OR ¼ 1.14, P ¼ 3.9 × 10213) but not
ER+ breast cancer (OR ¼ 0.99, P ¼ 0.7) (14). However, in
this region, we observed suggestive evidence of a signal for
ER+ breast cancer with a large cluster of alleles that are corre-
lated with the index variant in European ancestry populations,
the most significant of which was rs4951385 (OR ¼ 1.17, P ¼
1.2 × 1023). Variant rs4951385 is located 64.7 kb from the
index SNP (rs4245739) in the 32nd intron of the PIK3C2B
gene and is highly correlated with rs4245739 in European, but
not African ancestry populations (EUR: r2 ¼ 0.90; AFR: r2 ¼
0.11) (Supplementary Material, Table S4).
At 3q24, the index SNP (rs12493607) was positively asso-
ciated with overall breast cancer as well as ER+ and ER2
disease in African Americans (Supplementary Material,
Tables S1 and S3). Through fine-mapping, variant rs13086588
was detected to be more strongly associated with ER+ breast
cancer (ER+: OR ¼ 1.20, P ¼ 3.0 × 1024; ER2: OR ¼ 1.04,
P ¼ 0.54; phet ¼ 0.04), which is consistent with this locus
being more strongly associated with ER+ than ER2 disease
(phet ¼ 0.02) (12). Variant rs13086588 is located in the second
intron of TGFBR2, and is strongly correlated with rs12493607
in Europeans but not in African ancestry populations (EUR:
r2 ¼ 0.76; AFR: r2 ¼ 0.08; Supplementary Material, Table S4).
At 10q25, the index variant (rs7904519) was significantly
associated with the risk of overall breast cancer in African Amer-
icans (OR ¼ 1.13, P ¼ 0.01). Fine-mapping of this region
revealed variant rs7919152 that is correlated with the index
variant (rs7904519: EUR: r2 ¼ 0.83; AFR: r2 ¼ 0.51) and
may be better capturing risk of overall breast cancer in this
region (OR ¼ 1.16, P ¼ 9.9 × 1024; Supplementary Material,
Table S4).
In search of novel secondary signals at each risk locus, we
tested associations of all SNPs within 250 kb surrounding each
index variant with risk of overall breast cancer as well as ER+
and ER2 disease (see Materials and Methods for details). In
three of the 54 regions (6q25, 14q13, 22q12), we detected evi-
dence of an independent signal at P , 5 × 1026 (all SNPs
uncorrelated r2 , 0.05 with the index variants at P ≤ 1025 are
shown in Supplementary Material, Table S5). At 6q25, an inter-
genic variant, rs9390664, was found to be significantly asso-
ciated with overall breast cancer risk (OR ¼ 1.39, P ¼ 4.4 ×
1027). This variant is located 33.9 kb from the index SNP
(rs9485372) and is not correlated with rs9485372 in either Euro-
pean or African populations (r2 , 0.05). At 14q13, the index
variant rs2236007 was reported to be more significantly asso-
ciated with ER+ than ER2 breast cancer in Europeans
(OR ¼ 1.10 versus 1.04, phet ¼ 0.02) (12). We observed an asso-
ciation with rs17104923, located 6.4 kb from rs2236007 in the
4th intron of the PAX9 gene, which was also more strongly asso-
ciated with ER+ breast cancer (Overall: OR ¼ 1.28, P ¼ 1.1 ×
1023; ER+: OR ¼ 1.62, P ¼ 1.6 × 1026; ER2: OR ¼ 1.13,
P ¼ 0.27; phet ¼ 0.019; Supplementary Material, Table S5;
Fig. 2). Variant rs17104923 is not correlated with rs2236007
in either European or African populations (r2 , 0.01). At
22q12, the association with the index variant (rs132390) in Eur-
opeans was found to be stronger for ER+ disease (ER+: OR ¼
1.13, P ¼ 4.2 × 1025; ER2: OR ¼ 1.08, P ¼ 0.11). A second-
ary signal, rs67157227, located 100.4 kb from the index SNP
(rs132390) in the 4th intron of the KREMEN1 gene, was also
identified to be significantly associated with ER+ breast
cancer (Overall: OR ¼ 1.24, P ¼ 5.5 × 1025; ER+: OR ¼
1.36, P ¼ 4.4 × 1026; ER2: OR ¼ 1.12, P ¼ 0.13; phet ¼
0.031), suggesting that variation at this locus may also be more
associated with ER+ disease in African Americans.
In attempt to confirm these findings, we tested the three signifi-
cant secondary signals in an independent sample of 1657 breast
cancer cases and 2028 controls of African ancestry (see Materi-
als and Methods for details of this sample). Only one variant
(rs17104923/14q13) was significantly associated with breast
cancer risk (OR ¼ 1.20, P ¼ 0.036; Supplementary Material,
Table S6). The association was stronger with ER+ than ER2
disease (n ¼ 403 ER+ cases: OR ¼ 1.32, P ¼ 0.057; n ¼ 374
ER2 cases: OR ¼ 1.18, P ¼ 0.24), which is consistent with
the initial results in our study.
We also estimated the cumulative effects of all 73 breast
cancer risk variants using risk score modeling. The risk per
allele was 1.04 (95% CI: 1.03–1.05, P ¼ 1.6 × 10211) for
overall breast cancer, 1.04 (95% CI: 1.02–1.05, P ¼ 2.0 ×
1027) for ER+ disease and 1.03 (95% CI: 1.02–1.05, P ¼
1.1 × 1024) for ER2 disease. Compared with those in the
lowest quintile, individuals in the top quintile of the risk allele
distribution were at 1.78 (P ¼ 1.1 × 10210), 1.67 (P ¼ 1.8 ×
1026) and 1.70 (P ¼ 4.4 × 1025) -fold greater risk of overall
breast cancer, ER+ and ER2 disease, respectively (Table 1).
DISCUSSION
In this study of breast cancer in African American women, we
tested 54 recently identified variants with the vast majority iden-
tified through large-scale testing in the COGS consortium in
European-ancestry populations (1–15). We observed 38 var-
iants that were associated with overall or ER2 breast cancer
in African Americans in a direction consistent with that reported
previously. The 54 variants tested in this study were previously
reported to have an average odds ratio of 1.09, with only 13
(24%) having ORs .1.10. This is in contrast to the initial set
of 19 breast cancer risk variants discovered through GWAS,
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which had larger effect sizes, with nine (47%) variants having
ORs .1.10, and an average OR of 1.12. Thus, in general,
these new variants had smaller effect sizes, implying a weaker
biological influence on breast cancer (1–15). In our study in
African Americans, statistical power was ≥80% to detect a nom-
inally statistically significant association for eight (42%) of the
19 variants examined initially (16), while for only two (4%) of
these additional 54 variants did we have ≥80% power to
detect the odds ratios reported in the initial studies (Supplemen-
tary Material, Table S2).
Despite small effect sizes leading to limited power, failure of
replication may also result from different LD structure between
populations and more distinct markers of the index signal to re-
present the same biological signal in diverse populations. Using
our stringent criteria, in only three (6%) of the 54 recently iden-
tified breast cancer susceptibility regions did we identify variants
that might better define associations with overall breast cancer,
ER+ or ER2 disease in African Americans. The failure to
enhance signals in these regions might also be attributed to
limited statistical power. In utilizing the locus-specific a levels,
statistical power was ≥80% to detect associations for only five
of the 73 regions (Supplementary Material, Table S7). As
described earlier, in the initial GWAS, these newly identified
breast cancer risk variants had smaller odds ratios than the
initial 19 GWAS identified risk variants. Given the observed
diminishing effect sizes noted for the more recently identified
GWAS variants, even larger sample size is needed to detect asso-
ciations in non-European ancestry populations.
In three of the 54 regions, we observed significant associations
(P , 5 × 1026) with variants that were uncorrelated with the
index SNPs, representing putative novel independent risk
signals. At 14q13, the association with rs17104923 was stronger
for ER+ breast cancer, with supportive evidence provided in the
replication sample (P ¼ 0.04 for overall breast cancer and P ¼
0.06 for ER+ disease). Variant rs17104923 is located in the
4th intron of the gene PAX9 (paired box 9). In addition to it being
a risk locus for breast cancer (12), the chromosome region con-
taining PAX9 on 14q13 has also been shown to be both amplified
and deleted in lung cancer (19). Both the index variant at this
locus and this putative novel signal appear to be more strongly
associated with ER+ breast cancer, which provides further
support for genetic determinants of breast cancer subtypes. At
6q25, the intergenic variant rs9390664 is in close proximity to
a number of genes, including TAB2 (TGF-beta activated
kinase 1/MAP3K7 binding protein 2), SUMO4 (small ubiquitin-
like modifier 4) and UST (uronyl-2-sulfotransferase). At 22q12,
the variant rs67157227 is located in the 4th intron of KREMEN1
which is a component of a membrane complex that modulates ca-
nonical WNT signaling through lipoprotein receptor-related
protein 6 (LRP6) (20). According to data harvested from the
ENCODE project (21), only one of the suggestive secondary
signals (rs17104923/14q13) was found to be located in proxim-
ity to a weak DNaseI signal, which marks for a nucleosome
depleted region, in a breast cancer cell line (MCF7, ER+ cell
line). Further support for the associations with these variants is
needed as neither was found to be statistically significantly asso-
ciated with risk in the replication sample.
Among the 73 known risk loci, 49 (67%) showed an associ-
ation with overall breast cancer or ER2 disease in the same
direction as previously reported, with 12 (18%) showing direc-
tionally consistent and nominally statistically significant asso-
ciations in African Americans. The directional consistency
Figure 2. Regional plot of the secondary signal (rs17104923) on 14q13. The chromosomal position (based on GRCh37) of SNPs on 14q13 against –log10 P-values for
ER+ disease is shown. Genotyped SNPs are represented by circles. Imputed SNPs are represented by squares. The secondary signal rs17104923 is plotted by a purple
square. The red arrow denotes the GWAS index variant rs2236007. SNPs surrounding the top SNPs are colored to indicate the LD structure using pairwise r2 in ref-
erence to rs17104923 from the May 2012 AFR panel of 1000 Genomes. The plots were generated using LocusZoom (18).
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noted implies a shared functional common variant at most loci.
Long et al. (22) evaluated 67 breast cancer susceptibility loci
in a study with 1231 African American cases and 2069 controls.
Seven SNPs showed directionally consistent and significant
associations with overall breast cancer, four of which were repli-
cated in our African American sample. Through fine-mapping
conducted in this study and in our previous study (16), we
noted suggestive evidence in several regions with variants that
may better characterize the association with breast cancer risk
in African American women. As is currently ongoing for most
phenotypes, combining GWAS data from large numbers of
studies via meta-analyses followed by large-scale replication
testing will continue to reveal variants with diminishing effect
sizes. Additional studies in African ancestry populations and
combining genetic data through large collaborative efforts will
be needed in order to more fully understand the contribution to
risk of the established breast cancer loci, especially for ER2




The data in this study are from a GWAS of breast cancer in
African American women which includes nine epidemiological
studies of breast cancer, comprising a total of 3153 cases
and 2831 controls (cases/controls): the Multiethnic Cohort
study (MEC) (23), 734/1003; The Los Angeles component of
The Women’s Contraceptive and Reproductive Experiences
(CARE) Study (24), 380/224; The Women’s Circle of Health
Study (WCHS) (25), 272/240; The San Francisco Bay Area
Breast Cancer Study (SFBCS) (26), 172/231; The Northern Cali-
fornia site of the Breast Cancer Family Registry (NC-BCFR)
(27), 440/53; The Carolina Breast Cancer Study (CBCS) (28),
656/608; The Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial Cohort (PLCO) (29), 64/133; The Nashville
Breast Health Study (NBHS) (30), 310/186; and The Wake
Forest University Breast Cancer Study (WFBC) (31), 125/153.
Detailed information about the design of each study has been
published previously (16,32). Sample size and selected charac-
teristics for these studies are summarized in Supplementary Ma-
terial, Table S8.
The replication sample included six studies of African ances-
try and a total of 1657 cases and 2028 controls (cases/controls):
the Nigerian Breast Cancer Study (NBCS) (33,34), 711/623; The
Barbados National Cancer Study (BNCS) (35), 92/229; The
Racial Variability in Genotypic Determinants of Breast Cancer
Risk Study (RVGBC), 145/257; The Baltimore Breast Cancer
Study (BBCS), 95/102; The Chicago Cancer Prone Study
(CCPS), 394/387 and The Southern Community Cohort
(SCCS) (36), 220/430. Detailed information about the design
of each study is described in Zheng et al. (37).
Genotyping and quality control
Genotyping for the African American sample in this study was
conducted using the Illumina Human1M-Duo BeadChip as
described in Chen et al. (16). The average sample call rate was
Table 1. Associations with risk scores comprising 73 breast cancer risk variants in African Americans by ER status
All cases versus controls ER+ cases versus controls ER2 cases versus controls pheta
Average number of risk alleles in controls (range) 71.3 (55.0–86.4)
Per allele OR (95% CI)b 1.04 (1.03–1.05) 1.04 (1.02–1.05) 1.03 (1.02–1.05)
Ptrend
c 1.6 × 10211 2.0 × 1027 1.1 × 1024 0.36
n cases/n controls 3016/2745 1520/2745 988/2745
Risk quintilesd
Q1
n cases/n controls 515/637 272/637 157/637
OR (95% CI) 1.00 (reference) 1.00 (reference) 1.00 (reference)
P-value – – –
Q2
n cases/n controls 578/572 300/572 192/572
OR (95% CI) 1.24 (1.05–1.47) 1.22 (0.99–1.50) 1.31 (1.02–1.69)
P-value 0.014 0.063 0.036
Q3
n cases/n controls 628/527 306/527 218/527
OR (95% CI) 1.46 (1.23–1.73) 1.36 (1.10–1.68) 1.58 (1.23–2.03)
P-value 1.9 × 1025 4.1 × 1023 3.6 × 1024
Q4
n cases/n controls 615/538 302/538 201/538
OR (95% CI) 1.44 (1.21–1.71) 1.34 (1.09–1.66) 1.49 (1.16–1.92)
P-value 3.4 × 1025 6.3 × 1023 2.0 × 1023
Q5
n cases/n controls 680/471 340/471 220/471
OR (95% CI) 1.78 (1.49–2.12) 1.67 (1.36–2.07) 1.70 (1.32–2.19)
P-value 1.1 × 10210 1.8 × 1026 4.4 × 1025
aP-value for case-only analysis (ER+ versus ER2).
bOdds ratio per allele based on analysis adjusted for age, study and the first 10 eigenvectors.
cP-value based on 1-degree-of-freedom Wald x2 trend test.
dCut points based on the distribution of risk scores in controls.
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99.8%. To confirm imputation (discussed subsequently), geno-
typing of the three significant secondary signals (rs9390664/
6q25, rs17104923/14q13 and rs67157227/22q12) was per-
formed in 377 individuals from the MEC African American
sample. Two variants (rs17104923/14q13 and rs67157227/
22q12) could be genotyped and had consistent genotypes with
that from imputation, with an r2 of 0.99 and 0.86, respectively.
Statistical analysis
In order to generate a data set suitable for fine-mapping, we per-
formed genome-wide imputation using IMPUTE2 (38) to a
cosmopolitan panel of all 1000 Genomes Project subjects
(March 2012 release). Imputed SNPs with r2 . 0.8 (defined as
the observed variance divided by the expected variance) were
used in the fine-mapping analyses. For the 54 index variants
analyzed in this study, 16 were imputed and imputation quality
scores were .0.8 for 14. Variants rs11571833/13q13 and
rs132390/22q12 were imputed with scores 0.69 and 0.72,
respectively, and both SNPs had small minor allele frequencies
in the AFR population of the 1000 Genomes Project (rs11571833/
13q13: MAF¼ 0.0060; rs132390/22q12: MAF¼ 0.059).
For each typed and imputed SNP, odds ratios (OR) and 95%
CIs were estimated using unconditional logistic regression adjust-
ing for age (at diagnosis for cases and age at the reference date for
controls), study, and the first 10 eigenvectors from a principal
components analysis (39). For each SNP, we tested for allele
dosage effects using a 1-degree-of-freedom Wald x2 trend test.
To characterize alleles that might better represent the bio-
logically functional variant, we searched and tested LD
proxies among the genotyped and imputed SNPs that are corre-
lated (r2 ≥ 0.4) with the index SNP (within 250 kb or larger if the
index signal was contained within an LD block) in the GWAS
discovery population (European ancestry). Two regions, 5p15
and 20q11 were excluded from locus fine-mapping as our
African American sample was involved in the discovery of
these loci (10,13). Locus-specific alpha levels were utilized,
which accounts for multiple testing of correlated markers
when searching for a stronger marker of the index signal in an
African population (Supplementary Material, Table S7). It is cal-
culated by 0.05/the number of tag SNPs in the African population
(1000 Genomes, AFR) that capture (r2 ≥ 0.8) all SNPs corre-
lated with the index signal in the European population (1000
Genomes, EUR). To reduce false-positive signals for all
regions, we required the P-value of all the better markers to be
less than 0.01. In an attempt to eliminate minor fluctuations in
P-values for correlated SNPs, we also required the P-value to de-
crease by more than one order of magnitude compared with the
association with the index signal. For correlated SNPs that were
selected to be better markers, we also assessed phase to ensure
that the new risk allele is on the same haplotype as the GWAS-
reported risk allele in the European ancestry population.
We also looked for novel independent associations, focusing
on the genotyped and imputed SNPs that were uncorrelated with
the index signal in European ancestry populations (r2 , 0.4).
Here, we applied a significance criterion ofa ¼ 5 × 1026 for de-
fining novel associations as significant in each region, which is
an extension of the empirically determined Bonferroni correc-
tion used in Chen et al. (16) and is an approximation of the
total number of tests to capture (at r2 ≥ 0.8) all common risk
alleles across the 73 risk regions in the African American popu-
lation. These procedures were applied to the analysis of overall
breast cancer as well as in hypothesis-generating analyses strati-
fied by ER status.
To evaluate the combined effects of these risk markers, we
modeled the cumulative genetic risk of breast cancer using the
73 reported risk variants in African Americans. We summed
the number of risk alleles for each individual and estimated the
odds ratio per allele for this aggregate unweighted allele count
variable as an approximate risk score appropriate for unlinked
variants with independent effects of approximately the same
magnitude for each allele. We applied this risk score to overall
breast cancer, as well as ER+ and ER2 disease. Missing
values for ungenotyped markers were replaced with mean
allele counts in the whole population.
Replication testing
The replication sample was genotyped with the Illumina 2.5 M
array as described in Zheng et al. (37). For the three variants
tested in this paper (rs9390664/6q25, rs17104923/14q13
and rs67157227/22q12), only rs17104923 at 14q13 was geno-
typed (call rate of 99.8%). Variants rs9390664/6q25 and
rs67157227/22q12 were imputed with scores of 0.95 and 0.97,
respectively. Details of the imputation strategy used in the repli-
cation sample were described in Zheng et al. (37).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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